Study Design of the Diacerein in Patients With Covid-19

Study Design This is a randomized, placebo-controlled, double-blind trial pilot study designed to verify whether diacerein attenuates systemic inflammatory response in hospitalized patients with COVID-19. This study has been reviewed and approved by the Ethics Committee of the State University of Campinas (CAAE: 50440921.6.0000.5404). Study Population Forty patients with a confirmed diagnosis of COVID-19 will be enrolled in the study. The patients will be identified as those admitted to either Hospital Estadual Sumaré (Sumaré, Brazil) and Unicamp Clinical Hospital (Campinas, Brazil). After enrolment, patients will be randomized (n=20 per group) in a 1:1 fashion to receive either diacerein 50mg or placebo treatment every 12 hours for 10 days. Recruitment All patients admitted with COVID-19 who meet the inclusion and exclusion criteria will be invited to participate in the study. After reading and signing the informed consent form, the patient will be randomly allocated to two treatment arms. Randomization and Blinding After enrolment, patients will be randomized (n=20 per group) 1:1 to receive either diacerein 50 mg or placebo treatment every 12 hours for 10 days. The research electronic data capture (REDCap) platform will be used as a randomization system. Patients, investigators and other support staff will be blinded to the experimental therapy. The study drug, diacerein (Artrodar®-capsules 50mg) and placebo capsules (lactose and magnesium stearate), will be similar in size and appearance to maintain blinding. All laboratory analyses will be performed blinded to the treatment. Identification of the study drug will only occur after locking the dataset. Trial Intervention After randomization, patients allocated to the active treatment will receive 1 capsule of diacerein (Artrodar®, 50mg) orally every 12 hours for 10 days. Patients randomized to the placebo group will receive 1 capsule (lactose and magnesium stearate) orally every 12 hours for 10 days. There will be a dose adjustment of study medication (diacerein or placebo) to 1 capsule every 24 hours (decreased diacerein to 50 mg every 24 hours instead of every 12 hours) in participants who experience acute kidney injury with a rate of estimated glomerular filtration rate <30mL/min or requiring renal replacement therapy. If renal replacement therapy is required, the study drug will be administered immediately after dialysis. If the patient is intubated, the diacerein or placebo capsules will be opened and their contents will be placed in previously cleaned and properly identified nylon sachets. The sachet content will be dissolved in 10 to 20ml of distilled water in a 20ml syringe at the time of administration by the nursing in the presence of a researcher. The trial intervention will not delay or affect the patient's clinical management in accordance with local centre policies. Laboratory analyses On admission, the first blood sample will be collected before the first dose of study drug (Day 0), and then three and ten hours after the drug administration. Blood samples will also be collected on the second (Day 2), fifth (Day 5) and tenth (Day 10) day of treatment. With the exception of samples obtained on admission, blood samples will be collected after a 12-hour fast. Immediately after collection, all samples will be centrifuged at 3,500 rpm and frozen in liquid nitrogen for single batch processing. Inflammatory cytokines (c-reactive protein, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IFN-α2, IFN-β, IFN-γ, TNF-α, IP-10 GM-CSF) will be measured by multiplex immunoassay (Bio-Plex 200®, Bio-Rad) as well other markers such as troponin-T and D-dimer measurements. Study Endpoints The endpoints are the change in the serum levels of cytokines, troponin-T and D-dimer from Day 0 to Day 5 of hospitalization, and from Day 0 to Day 10, as well as the area under the curve considering all measurements from Day 0 to Day 10. Secondary endpoints include (i) time to clinical deterioration defined as time from randomization to mortality or worsening of the World Health Organization (WHO) Clinical Progression Scale, assessed by the increase of two points in this scale; (ii) cumulative incidence of adverse events; (iii) cumulative incidence of severe adverse events. Diacerein Bioavailability The bioavailability of diacerein and its active metabolite, rhein, will be evaluated in the serum of patients randomized to diacerein treatment in order to assure the bioavailability in COVID-19 patients. It will be used samples from Day 0 and timepoints: soon before, three and ten hours after the study drug administration. All patients will have these samples collected to maintain study blinding. Serum diacerein and rhein concentrations will be determined by liquid chromatography-tandem mass spectrometry at the end of the study. Sample Size Calculation As there are no data available on the effect of diacerein on the inflammatory response in patients with COVID-19 the sample size was empirically established at 40 subjects in a conservative expectation of small standardized effect size (0.2). Therefore, we decided to carry out a pilot sample with 40 patients (n=20 per arm of the study) with outcomes from systemic inflammatory response and safety. The Safety Analysis Population Applied to all randomized patients who received at least one dose of diacerein. The safety assessment will be based on the cumulative incidence of safety outcomes, adverse events, physical examinations, vital signs, and safety laboratory tests. The primary safety endpoint will be the time between randomization and the first occurrence. Statistical Analysis Continuous variables will be represented by the median and the associated interquartile range. Categorical variables will be presented as absolute frequency (n) and relative frequency (%). Summary statistical data (mean, standard deviation, median, minimum and maximum) will be provided by the treatment group for demographic and baseline characteristics using a chi-square test (e.g., categorical variables) and one-way analysis of variance (ANOVA) model with treatment as a factor (e.g., continuous variables). In addition, demographics and baseline characteristics will be compared across treatment groups for the intention to treat (ITT) population. The significance of this test will be used as an initial assessment for the satisfaction of randomization. Concentrations of plasma pro-inflammatory cytokines will be considered as efficacy endpoints. The groups will be compared by the changes in admission (Day 0) versus assessment days (Day 2, Day 5 and Day 10). Also, comparison between the areas under the curve for each of the parameters from Day 0 to Day 10. Continuous variables with normal and non-parametric distribution will be compared by analysis of covariance (ANCOVA) or by analysis of rank of variance (RANKOVA) adjusted by baseline values to mitigate the regression toward the mean.